Headlines about Agenus (NASDAQ:AGEN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Agenus earned a news impact score of 0.24 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.8412411034763 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

Several brokerages have weighed in on AGEN. BidaskClub raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 target price on shares of Agenus in a research report on Friday, August 4th. Zacks Investment Research raised Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Wednesday, July 5th. Finally, HC Wainwright set a $5.00 target price on Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.88.

Shares of Agenus (NASDAQ AGEN) traded up 2.01% on Friday, hitting $3.55. The stock had a trading volume of 746,003 shares. The company’s market cap is $353.98 million. The firm has a 50 day moving average price of $4.30 and a 200-day moving average price of $3.90. Agenus has a 52 week low of $3.20 and a 52 week high of $7.49.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The business had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $6.66 million. During the same period in the previous year, the firm earned ($0.33) earnings per share. The firm’s quarterly revenue was down 36.1% compared to the same quarter last year. Analysts anticipate that Agenus will post ($1.13) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Agenus (AGEN) Stock Price” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-agenus-agen-stock-price.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Insider Buying and Selling by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Stock Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related stocks with our FREE daily email newsletter.